Economic evaluation of a lifestyle intervention in primary care to prevent type 2 diabetes mellitus and cardiovascular diseases: A randomized controlled trial

BMC Family Practice

Volumn 14, Issue , 2013, Pages

  Van Wier, Marieke F ^a,c   Lakerveld, Jeroen ^a   Bot, Sandra D M ^a   Chinapaw, Mai J M ^a   Nijpels, Giel ^a   Van Tulder, Maurits W ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Cost effectiveness; Cost utility; General practitioner; Lifestyle counseling; Practice nurse

Indexed keywords

ADULT; CARDIOVASCULAR DISEASES; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DIABETES MELLITUS, TYPE 2; DIRECTIVE COUNSELING; DRUG COST; ECONOMICS; FEMALE; HEALTH BEHAVIOR; HEALTH PROMOTION; HEALTH SERVICE; HUMAN; LIFESTYLE; MALE; MIDDLE AGED; NETHERLANDS; PATIENT EDUCATION; PRIMARY HEALTH CARE; PUBLICATION; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; UTILIZATION;

ADULT; CARDIOVASCULAR DISEASES; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIRECTIVE COUNSELING; DRUG COSTS; FEMALE; HEALTH BEHAVIOR; HEALTH PROMOTION; HEALTH SERVICES; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; NETHERLANDS; PAMPHLETS; PATIENT EDUCATION AS TOPIC; PRIMARY HEALTH CARE; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS;

EID: 84875689413     PISSN: None     EISSN: 14712296     Source Type: Journal    
DOI: 10.1186/1471-2296-14-45     Document Type: Article

References (34)

1. The global burden of diabetes and its complications: an emerging pandemic. van Dieren S, Beulens JW, van der Schouw YT, Grobbee DE, Neal B, Eur J Cardiovasc Prev Rehabil 2010 17 Suppl 1 3 S8 20489418
2. Health and economic burden of the projected obesity trends in the USA and the UK. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M, Lancet 2011 378 815 825 10.1016/S0140-6736(11)60814-3 21872750
3. Effects of lifestyle changes to reduce risks of diabetes and associated cardiovascular risks: results from large scale efficacy trials. Horton ES, Obesity (Silver Spring) 2009 17 Suppl 3 43 S48
4. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X, Diabetes Care 2010 33 1872 1894 10.2337/dc10-0843 20668156
5. Primary prevention of diabetes mellitus type 2 and cardiovascular diseases using a cognitive behavior program aimed at lifestyle changes in people at risk: design of a randomized controlled trial. Lakerveld J, Bot SD, Chinapaw MJ, van Tulder MW, van Oppen P, Dekker JM, BMC Endocr Disord 2008 8 6 10.1186/1472-6823-8-6 18573221 (Pubitemid 352022545)
6. Process evaluation of a lifestyle intervention to prevent diabetes and cardiovascular diseases in primary care. Lakerveld J, Bot S, Chinapaw M, van Tulder M, Kingo L, Nijpels G, Health Promot Pract 2012 13 696 706 10.1177/1524839912437366 22773615
7. Waist circumference and cardiometabolic risk: a consensus statement from shaping America's health: association for weight management and obesity prevention; NAASO, the obesity society; the American society for nutrition; and the American diabetes association. Klein S, Allison DB, Heymsfield SB, Kelley DE, Leibel RL, Nonas C, Obesity (Silver Spring) 2007 15 1061 1067 10.1038/oby.2007.632 (Pubitemid 46932459)
8. International Day for the evaluation of abdominal obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Balkau B, Deanfield JE, Despres JP, Bassand JP, Fox KA, Smith SC Jr, Circulation 2007 116 1942 1951 10.1161/CIRCULATIONAHA.106.676379 17965405 (Pubitemid 350287090)
9. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De BG, Eur Heart J 2003 24 987 1003 10.1016/S0195-668X(03)00114-3 12788299 (Pubitemid 36712275)
10. EuroQol Group: EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990 16 199 208 10109801
11. Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff. Lamers LM, Stalmeier PF, McDonnell J, Krabbe PF, van Busschbach JJ, Ned Tijdschr Geneeskd 2005 149 1574 1578 16038162 (Pubitemid 40978328)
12. Identifying individuals at high risk for diabetes: the atherosclerosis risk in communities study. Schmidt MI, Duncan BB, Bang H, Pankow JS, Ballantyne CM, Golden SH, Diabetes Care 2005 28 2013 2018 10.2337/diacare.28.8.2013 16043747 (Pubitemid 41060977)
13. Prediction of coronary heart disease risk in a general, pre-diabetic, and diabetic population during 10 years of follow-up: accuracy of the Framingham, SCORE, and UKPDS risk functions: the Hoorn study. van der Heijden AA, Ortegon MM, Niessen LW, Nijpels G, Dekker JM, Diabetes Care 2009 32 2094 2098 10.2337/dc09-0745 19875606
14. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH, Dutch manual for costing: methods and standard costs for economic evaluations in health care Diemen, The Netherlands: Dutch Health Care Insurance Board 2004
15. Z-Index, G-standaard [G-standard] The Hague: The Netherlands, Z-Index 2006
16. Statistics Netherlands, Consumer price indices Netherlands: Statistics Netherlands 2011
17. Multiple imputation of missing blood pressure covariates in survival analysis. Van Buuren S, Boshuizen HC, Knook DL, Stat Med 1999 18 681 694 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.0.CO;2-R 10204197 (Pubitemid 29126744)
18. Multiple imputation of discrete and continuous data by fully conditional specification. Van Buuren S, Stat Methods Med Res 2007 16 219 242 10.1177/0962280206074463 17621469 (Pubitemid 47018660)
19. Rubin DB, Multiple imputation for nonresponse in surveys New York: J. Wiley & Sons 1987
20. Evaluation of the results of a randomized controlled trial: how to define changes between baseline and follow-up. Twisk J, Proper K, J Clin Epidemiol 2004 57 223 228 10.1016/j.jclinepi.2003.07.009 15066681 (Pubitemid 38456873)
21. The CE plane: a graphic representation of cost-effectiveness. Black WC, Med Decis Making 1990 10 212 214 10.1177/0272989X9001000308 2115096 (Pubitemid 20311440)
22. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. Fenwick E, Marshall DA, Levy AR, Nichol G, BMC Health Serv Res 2006 6 52 10.1186/1472-6963-6-52 16623946 (Pubitemid 44219742)
23. R Development Core Team, R: A language and environment for statistical computing Vienna, Austria: R Foundation for Statistical Computing 2008
24. Rodenburg-van Dieten HEM, Guidelines for pharmacoeconomic research; evaluation and update. 24088606 Diemen, The Netherlands: Dutch Health Care Insurance Board 2005 23585642
25. Multiple imputation using chained equations: issues and guidance for practice. White IR, Royston P, Wood AM, Stat Med 2011 30 377 399 10.1002/sim.4067 21225900
26. Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions. Fenwick E, O'Brien BJ, Briggs A, Health Econ 2004 13 405 415 10.1002/hec.903 15127421 (Pubitemid 38660390)
27. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Qual Life Res 2011 20 1727 1736 10.1007/s11136-011-9903-x 21479777
28. Health literacy revisited: what do we mean and why does it matter? Peerson A, Saunders M, Health Promot Int 2009 24 285 296 10.1093/heapro/dap014 19372101
29. The costs of limited health literacy: a systematic review. Eichler K, Wieser S, Brugger U, Int J Public Health 2009 54 313 324 10.1007/s00038-009- 0058-2 19644651
30. Dutch Council for Public Health and Health Care, Zinnige en duurzame zorg [Sensible and sustainable care] Zoetermeer, The Netherlands: Raad voor Volksgezondheid en Zorg 2006
31. Cost-effectiveness acceptability curves and a reluctance to lose. Severens JL, Brunenberg DE, Fenwick EA, O'Brien B, Joore MA, PharmacoEconomics 2005 23 1207 1214 10.2165/00019053-200523120-00005 16336015 (Pubitemid 41803317)
32. Potential savings of a program to prevent ankle sprain recurrence: economic evaluation of a randomized controlled trial. Hupperets MD, Verhagen EA, Heymans MW, Bosmans JE, van Tulder MW, van Mechelen W, Am J Sports Med 2010 38 2194 2200 10.1177/0363546510373470 20699429
33. Cost-effectiveness of a minimal intervention for stress-related sick leave in general practice: results of an economic evaluation alongside a pragmatic randomised control trial. Uegaki K, Bakker I, de Bruijne M, van der Beek A, Terluin B, van Marwijk H, J Affect Disord 2010 120 177 187 10.1016/j.jad.2009.04.012 19439362
34. Whither trial-based economic evaluation for health care decision making? Sculpher MJ, Claxton K, Drummond M, McCabe C, Health Econ 2006 15 677 687 10.1002/hec.1093 16491461 (Pubitemid 44057239)